European Urology Names Fox Chase Cancer Center’s Dr. Andres F. Correa Reviewer of the Month

Andreas Correa European Reviewer of the Month
The journal European Urology has named Fox Chase Cancer Center urologic oncologist Andres F. Correa, MD, its March 2024 Reviewer of the Month.

PHILADELPHIA (March 20, 2024) – The journal European Urology has named Fox Chase Cancer Center urologic oncologist Andres F. Correa, MD, its March 2024 Reviewer of the Month.

“I am truly honored by this distinction from European Urology and having the privilege of being a reviewer of the cutting-edge urologic oncology research submitted to the journal. Involvement in the review process for this prestigious journal has allowed me to remain inquisitive and current with our fast-evolving field. It goes hand in hand with my role as Director of Research in the Department of Urology here at Fox Chase,” said Correa, who is also an Assistant Professor in the department and the Society of Urologic Oncology’s Fellowship Director.

“This huge international recognition by the top journal in our field is a testament to Dr. Correa’s exceptional expertise and dedication,” said Alexander Kutikov, MD, FACS, Chair of the Department of Urology. Correa, who was a Society of Urologic Oncology Fellow at Fox Chase, returned to the center in 2020. He received his medical degree from the University of Maryland School of Medicine, where he graduated magna cum laude. Correa was a general surgery intern at the University of Pittsburgh Medical Center before becoming a urology resident and eventually the urology chief resident.

Correa is skilled at all surgical modalities, including robotics, laparoscopy, and traditional open surgery, and has deep expertise in prostate, kidney, bladder, testicular, and other genitourinary cancers.

“Fox Chase Urologic Oncology is extremely fortunate to be home to talent of such high caliber,” said Kutikov.

Correa is a member of the American Medical Association, National Hispanic Medical Association, American Urological Association, and the Society of Urologic Oncology.

He has published numerous manuscripts in peer-reviewed journals, including seminal work on prediction of kidney cancer recurrence in the prestigious Journal of Clinical Oncology, and has presented at numerous academic meetings and contributed to book chapters in the field.

Correa was named a Top Doctor by Philadelphia magazine. He is fluent in Spanish and has been nominated as a top doctor in the Philadelphia area by Al Día News Media.

Fox Chase Cancer Center (Fox Chase), which includes the Institute for Cancer Research and the American Oncologic Hospital and is a part of Temple Health, is one of the leading comprehensive cancer centers in the United States. Founded in 1904 in Philadelphia as one of the nation’s first cancer hospitals, Fox Chase was also among the first institutions to be designated a National Cancer Institute Comprehensive Cancer Center in 1974. Fox Chase is also one of just 10 members of the Alliance of Dedicated Cancer Centers. Fox Chase researchers have won the highest awards in their fields, including two Nobel Prizes. Fox Chase physicians are also routinely recognized in national rankings, and the Center’s nursing program has received the Magnet recognition for excellence six consecutive times. Today, Fox Chase conducts a broad array of nationally competitive basic, translational, and clinical research, with special programs in cancer prevention, detection, survivorship, and community outreach. It is the policy of Fox Chase Cancer Center that there shall be no exclusion from, or participation in, and no one denied the benefits of, the delivery of quality medical care on the basis of race, ethnicity, religion, sexual orientation, gender, gender identity/expression, disability, age, ancestry, color, national origin, physical ability, level of education, or source of payment.

For more information, call 888-369-2427